Anna Durbin
Affiliations: | International Health | Johns Hopkins University, Baltimore, MD |
Area:
Public Health, EpidemiologyGoogle:
"Anna Durbin"Cross-listing: Epi Tree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pierce KK, Durbin AP, Walsh MC, et al. (2023) TV005 dengue vaccine protects against dengue serotype 2 and 3 controlled human infection. The Journal of Clinical Investigation |
| Walsh MR, Alam MS, Pierce KK, et al. (2023) Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. The Lancet. Infectious Diseases |
| Odio CD, Lowman KE, Law M, et al. (2023) Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine. Bmc Infectious Diseases. 23: 345 |
| Pintado Silva J, Fenutria R, Bernal-Rubio D, et al. (2023) The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature. Experimental Biology and Medicine (Maywood, N.J.). 247: 2201-2212 |
| Wilder-Smith A, Durbin A. (2023) Promising efforts to develop an mRNA vaccine against Zika. The Lancet. Infectious Diseases |
| Wong JM, Adams LE, Durbin AP, et al. (2022) Dengue: A Growing Problem With New Interventions. Pediatrics |
| Hou R, Tomalin LE, Silva JP, et al. (2022) The innate immune response following multivalent dengue vaccination and implications for protection against dengue challenge. Jci Insight |
| Santiago HC, Pereira-Neto TA, Gonçalves-Pereira MH, et al. (2022) Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model. Pathogens (Basel, Switzerland). 11 |
| Falsey AR, Sobieszczyk ME, Hirsch I, et al. (2021) Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. The New England Journal of Medicine |
| Fongwen N, Delrieu I, Ham LH, et al. (2021) Implementation strategies for the first licensed dengue vaccine: A meeting report. Vaccine |